Sage Journals: Discover world-class research

Abstract

Cicatricial alopecia is a rare, clinically diversified set of disorders causing permanent and irreversible hair loss, which often results in serious discomfort and patient’s mental problems.

Clinically, this form of irreversible hair loss is characterized by visible loss of hair follicle openings in the bald spots. Histologically, it consists in destroying a hair follicle and replacing it with fibrocartilage. Such disorders are perceived as primary if a hair follicle itself is the target of the disease process and secondary if hair follicles are damaged incidentally in the context of more general tissue damage (e.g. deep skin infections, thermal burns, trauma or ionizing radiation).

In this article we tried to summarize the knowledge on possible pathogenic mechanisms of cicatricial alopecia. The presented factors usually overlap and affect prognosis of particular patients. Their profound understanding may enable further research on the treatment methods of this challenging disease unit.

Keywords

cicatricial alopecia etiology inflammation

Clinical features of cicatricial alopecia

Cicatricial alopecia is a rare, clinically diversified set of disorders causing permanent and irreversible hair loss, which often results in serious discomfort and patient’s mental problems. The classification is based on the clinical picture and histopathology results.¹

Table 1.

Etiology of cicatricial alopecia (Braun-Falco et al.).

Genetic	Physical causes	Tumors	Infectious diseases	Various
Darier disease	Radiation	Metastases	Furunculus	DLE
Folliculitis decalvans	Burns	Carcinoma basocellulare	Lepra	Pemphigoid cicatricans
EBH	Chemical causes	Other tumors of the skin	Syphilis	Pustulosis eosynophylica
Ichthyosis	Mechanical causes	Carcinoma spinocellulare	Perifolliculitis abscendens et suffodiens	GVHD
Chondrodysplasia punctate		Hemangiomas	Tinea	LSA
Incontinentia pigmenti		Lymphomas	Herpes zoster	Lichen planus
				Sarcoidosis
				Sarkoidoza
				Morphea

Classification of cicatricial alopecia

According to the European classification, the group of cicatricial alopecia also includes an atrophic alopecia with inflammation as a damaging agent. Clinically, skin becomes thinner and the number of hair follicles decreases. A so-called brush symptom caused by the remaining tufts of hair, is also typical for atrophic alopecia. Histopathology is dominated by the decrease or complete disappearance of hair follicles with preserved arrector pili muscles and fibrous sheaths, perpendicular to the epidermis. There may be also perivascular lymphocytic infiltrates. The infiltrates around a hair follicle indicate concomitant disease. Some authors as the prototype of atrophic alopecia consider Pseudopelade of Brocq as well as alopecias including lichen planus and discoid lupus erythematosus (DLE).^1,3,4

In the American nomenclature, pseudopelade is diagnosed only when all other diseases are excluded. However, it is not known whether it is a separate disease entity or the end stage of other dermatoses (Table 2).¹

Table 2.

Differentation of the pseudopelade (Braun-Falco et al.).

Common causes	Rare causes
Folliculitis decalvans	Necrobiosis lipoidica
Lichen planus	Granuloma annulare
DLE	Sarcoidosis
Morphea	Metastases
	Tinea

In 2011, Sperling presented an alternative classification of cicatricial alopecia. It was divided into five separate subtypes: (1) chronic lupus erythematosus (DLE); (2) lichen planus; (3) perifolliculitis capitis abscedens et suffodiens; (4) acne keloidans nuchae; and (5) pseudopelade.^5,6

Etiology of cicatricial alopecia

There are numerous theories regarding the etiology of cicatricial alopecia.

Given a great number of separate populations of hair follicles’ stem cells, their ability to induce angiogenesis and the growth of nerve fibers, an important role in wound healing and underestimated impact on the overall skin architecture and physiology – permanent loss of pilosebaceous units is a problem of the whole skin that affects its normal functioning and regenerative potential. The result of such alopecia is an irreversible damage of epithelial hair follicle stem cells to such extent that this mini organ is no longer able to grow and regenerate due to an inflammatory attack on follicle. Therefore, cicatricial alopecia is a good subject for studies on immune deregulations resulting in the inflammatory damage of epithelial stem cell populations. In addition, it is an exemplary system in which the attack is caused by unknown factors. It can be observed in humans and in mouse models, showing the phenotype of cicatricial alopecia, how the epithelial stem cells are protected in the event of self-harm, and what recovery strategies apply. It can also be noted what exactly defines the place where the damage of the epithelial stem cells becomes irreversible and leads to their apoptosis or necrosis.^7–9

Mammalian hair growth cycle includes the phases of active growth (anagen) intertwining with massive apoptosis of hair follicle (catagen) and periods of relative calm (telogen). This constant lifelong activity of hair follicle rebuilding depends on the presence of its functional stem cells (eHFSCs). The cells are located at the site of the arrector pili muscle attachment, in the outermost layer of the hair root, that is, hair bulb.^9,10

An abnormal immune response that destroys eHFSCs, probably plays a role in the etiology of cicatricial alopecia. It is believed that hair follicles can be the gate to the microbial invasion on the mammal skin. However, in the case of the immunocompetent patients, a clinical consequence of this invasion (e.g. bacterial or fungus folliculitis) is exceptionally rare. Such observation suggests that hair follicle must have the efficient anti-infection mechanisms.¹¹

The hair follicle epithelium is richly endowed with T lymphocytes and the Langerhans cells and surrounded by elements of the innate and cellular immunity (e.g. follicular mast cells and macrophages). It also indicates the activity of such antimicrobial peptides as human β2 defensin and cathelicidin. The last two inform about the danger and, together with pro-inflammatory cytokines and chemokines released by the hair follicle epithelium, can cause the accumulation of immunocytes to the point at which neutrophils, macrophages, and T-lymphocytes attack and potentially destroy the hair follicle epithelium.^11,12

On the other hand, the hair follicle immune system has created a complex system of control and balance and the latter inhibits inflammation. Large areas of hair follicle epithelium are subjected to the action of endogenous immunosuppressive factors such as transforming growth factor (TGF)-β1/2 and α-melanocyte stimulation hormone (MSH). In the physiological conditions, even the follicular mast cells can have the inhibitory effect on the immune system.

The divisions of the hair follicle epithelium (anagen) create the space of relative privilege (immune IP). This condition is characterized by low or complete lack of the expression of major (MHC) class I and class II antigens, as well as this of local immunosuppressant molecules including the synthesis of interfollicular cortisol. All of this can not only be used for the defence against damaging inflammation of a hair follicle, resulting from minor trauma, skin irritation, or microbial invasion, but also to eliminate potentially immunogenic autoantigens.^13–15

In the context of the pathogenesis of primary cicatricial alopecia, it seems to be important that a so-called immune privilege concerns also a hair bulb and eHFSCs. The levels of the expression of MHC class I antigens and β2-microglobulin and MHC class II are significantly reduced, whereas the immunoreactivity for locally generated immunosuppressant such as TGF-β2 and the factor inhibiting macrophage activity is increasing.¹⁶

However, a functional meaning of these protective mechanisms in hair follicles remains the subject of speculation. They have probably evolved to reduce the risk of autoimmune alopecia developing in mammals and possibly endangering their lives (e.g. consequences of hair loss for polar bears). Another theory is that a hair follicle protects eHFSCs in order to maintain at least a critical regeneration level of stem cells.^17,18

The key to understanding the pathogenesis of primary cicatricial alopecia is the location of follicular inflammatory infiltrate in relation to the two main structures of a hair follicle, namely a hair bulb and the location of eHFSCs. In reversible conditions like alopecia areata, an inflammatory infiltrate centers on a hair bulb; whereas in the case of cicatricial alopecia it concerns a hair bulb and a distal part of a hair follicle. This considerable difference in the location of inflammatory infiltrate has serious clinical consequences (reversible versus permanent hair loss).

The damage of eHFSCs seems to be a key element in the pathogenesis of cicatricial alopecia. Additionally, the cells in an inflammatory infiltrate are mainly located around the dystal part of a hair follicle, saving proximal elements. Interesting as it is, permanent hair loss may also occur in the case of prolonged androgenic alopecia and acute form of Graft versus Host disease in which an inflammatory infiltrate around the hair bulb is often observed.

These results, together with the model of transgenic mice K15 22, support the theory of the key role of destroying or damaging eHFSC in the case of cicatricial alopecia. However, as pointed out in the mouse model, the destruction of eHFSC does not fully explain the phenotypic profile of alopecia (e.g. atrophy, erythema). Therefore, other pathogenic processes should also be considered in the etiology. The question is why the hair follicle is the first to be attacked (which is a target antigen). It still has not been established what prevents the damage of eHFSCs in regular follicles. Are normal mechanisms of immune protection significantly disrupted and therefore whether eHFSCs are at risk of being damaged by the immune system attack? An unknown trigger may possibly be a signal to destroy eHFSCs which would eliminate hair follicle ability to regenerate and self-repair and at the same time to stimulate all other clinical and histopathological features of the disease.^19–22

The theory of the immune attack on eHFSCs is crucial for the etiology of cicatricial alopecia. MHC class I, β2- macroglobulin and MHC class II are subjected to different regulation within a hair bulb in the various cicatricial alopecia units compared to those in the not affected skin. However, it is still not clear whether this phenomenon develops at the onset of the disease or as the second component of the response induced by the environment of pro-inflammatory cytokines.

Due to the inflammation theory of cicatricial alopecia, many authors try to examine the potential role of cellular cytotoxicity in the pathogenesis of the disease. The inflammatory infiltrate is composed mainly of activated T lymphocytes. T cells with active chemokine receptors are often found within the scars, which suggests that they are involved in damaging a tissue through the attack and induction of apoptosis.^23,24

Other noticeable cellular changes are, among others, increased number of plasmacytoid dendritic cells along with the increase in the expression of adhesion molecules (e.g. intercellular adhesion molecule-1, vascular molecule of cell adhesion, and E-selectin). As in the case of many inflammatory diseases, INF is a key cytokin in the pro-inflammatory response. Local production of INF induced the Th1 chemotaxis via different chemokines (e.g. CXCL9,10) to affected areas of the skin. Interestingly, CXCL10 is expressed mainly in the stratum basale, in the areas of cytotoxic T cell invasion. There is also an increase in the activity of tumor necrosis factor (TNF), interleukin-2 and INF-γ.^25–27

Wenzel suggested the following mechanism of the initiation of an inflammatory response: the Type 1 of the INF expression is caused by the absence of a stimulus which induces chemokines and the production of antiviral proteins, which, in turn, attracts T cells and dendritic cells to the skin. What is more, an ongoing inflammatory response^28–30 is fixed by the release of inflammatory cytokines from dendritic cells and accumulated apoptotic cells, together with the direct chemokine release from T cells.

Apoptosis is increased in the hair follicle, epidermis, and inflammatory infiltrate. Interesting as it is, the expression of the apoptosis Bcl-2 inhibitor is also reduced, which predisposes to apoptosis related to the tissue damage.³¹

The hypothesis that disorders of the sebaceous gland may play a role in the pathogenesis of cicatricial alopecia comes from the observations of spontaneous mutations in mice assigned the name asebia (SCD1 AB), which exhibit the phenotype of cicatricial alopecia. In this model, hair is sparse, whereas hair follicles are either absent and replaced by fibrous tissue. The defect of stearoyl-CoA desaturase 1, a crucial component of fatty acids, causes the atrophy of the sebaceous glands, which leads to the hair growth disorder and potential destruction of the hair follicle. However, even though the sebaceous glands are atrophic or absent in the early stages of the disease, the phenomena has not been described in humans. However, despite the fact that the mice model explains general pathologic mechanisms of cicatricial alopecia, promoting the hypothesis that the dysfunction of the sebaceous gland is crucial, there is no evidence that it also applies to humans.^32,33

The research carried out on 90 skin samples from patients suffering from cicatricial and non-cicatricial alopecia showed that the number of sebaceous glands has decreased. The study also specified the role of the glands and their inflammation in the pathogenesis. The loss of the sebaceous glands was significantly more frequent in patients diagnosed with pseudopelade (more than 53%) than in the case of patients with non-cicatricial alopecia ( less than 5%). According to the quoted statement, the loss of the sebaceous glands and excretory duct inflammation may be important in initiating or accelerating damaging hair follicles during the development of the disease.³⁴

These possible mechanisms divided researchers into two groups: supporters of destroying eHFSC and those who claim that sebaceous gland dysfunction is a key matter. The analysis of the human genes expression confirmed a shortage of the peroxisome proliferator-activated receptor (PPAR)-γ, which indicates that also the damage of the lipid metabolism and peroxisome processing may be important in the pathogenesis of cicatricial alopecia. PPAR-γ mediates in transferring the signals via corresponding endogenous ligands, which may be necessary in order to maintain a regular functioning of hair follicle stem cells. Since we have access to the PPAR-γ antagonists such as pioglitazone, this treatment strategy may turn out effective in treating some forms of cicatricial alopecia.³⁵

Karnik et al.³⁶ presented the gene expression profile, which confirmed that changes in lipid metabolism are typical for every subtype of cicatricial alopecia. He also emphasized the role of PPAR-γ and other nuclear receptors in the pathogenesis. PPAR-γ is a transcription factor, which constitutes the family of nuclear receptors and turned out to be a vital regulator of the genes responsible for lipid metabolism and inflammation. It is most likely that lipid metabolism disorders in cicatricial alopecia precede inflammation and are caused by an error in the PPAR-γ signaling in the stem cells of the hair follicle and sebaceous glands. Other authors pointed out that PPAR transcription factor, which integrates lipogenic factors, plays a role in the pathogenesis of primary cicatricial alopecia. It is unknown, however, what initiates inflammation and whether it is a primary or secondary phenomenon in the disease pathogenesis and whether the inflammation reflects the autoimmune process. In this article, the author presented that the cholesterol biosynthesis in the skin and hair follicles is weakened in patients suffering from cicatricial alopecia, and the treatment with cholesterol biosynthesis inhibitors or 7-dehydrocholesterol (7-DHC), the precursor of sterols, stimulates the expression of the genes encoding pro-inflammatory chemokines. The reaction associated with the induction of Toll-like receptor (TLR) probably initiates the damage of hair follicles.³³

Programmed cell death is a crucial tool during tissues’ development and physiological remodeling, e.g. during morphogenesis and involution of the hair follicle in the catagen phase. Therefore, it was also suggested that apoptosis is a physiological mechanism for removing damaged abnormal hair follicles and thus primary cicatricial alopecia can be an uncontrolled variant of proper response pattern to serious damage. ³⁷

The psycho-emotional stressors in mice have a profound effect on hair growth through, among others, induction of nerve growth factor (NGF) and an increased release of substance P (SP), which increases the neurogenic skin inflammation. It results in severe follicular inflammatory infiltrates around a hair bulb, accumulation and degranulation of follicular mast cells, increased apoptosis of hair follicle keratinocytes, and reduction of the keratinocyte proliferation to premature entry into catagen.^38,39 It is also potentially important that the nerve fibers are particularly densely distributed around the arrector pilli muscle attachment and hair bulb. Follicular inflammation is often centered around these places. It was also shown that in the case of human hair follicles, stress induces catagen, increases mast cell degranulation in the anagen hair follicle, and regulates the expression of antigens MHC class I and β2-microglobuline.^40–43

Various environmental factors are concerned as triggers of cicatricial alopecia (e.g. infection, trauma, drugs).⁴⁴

A particular importance has also been attached to the infectious factors, e.g. folliculitis decalvans, whereas Staphylococcus aureus is commonly isolated from the affected skin areas. However, taking into consideration the frequency of isolation of the above mentioned bacteria in the general population (20–30%), it is likely that an abnormal host response to staphylococcal infection plays a key role in the development of the disease. One of the theories says that S. aureus produces toxins, a so-called superantigen, which can create complexes with abnormal MHC class II antygens, which in turn stimulates the proliferation of T cells.⁴⁵

Trauma also plays a role in the pathogenesis of different types of cicatrcial alopecia. In the parietal forms, the history of traumatic hair care practices is common (pulling). Folliculitis decalvans and erosive pustular dermatosis of the scalp are also associated with trauma and represent a so-called “nonspecific inflammatory reaction to trauma associated with solar radiation and with age”.⁴⁶ Pharmacological treatment can be also associated with the development of cicatricial alopecia, e.g. Graham Little syndrome may occur following hepatitis B, vaccination. Folliculitis decalvans can be associated with anticonvulsant therapy and cyclosporine.^47–50

Genetic factors may be a key element of the pathogenesis of all the forms of cicatricial alopecia, either because of a person predisposed to some kind of disorder or through direct genetic influence. The influence of environmental and genetic factors can be confirmed by reviewing the family history of various diseases, e.g. folliculitis decalvans in the case of identical twins, family cases of pseudopelade Brocq. Interestingly, a leukocyte antigen DR1⁵¹ could be observed in the case of mother and daughter suffering from Graham Little syndrome. While describing two identical twins diagnosed with pseudopelade Brocq, Singh et al.⁵² also discussed whether there may be a genetic cause associated with this type of hair loss.

Diagnosis of cicatricial alopecia

Cicatricial alopecia should be considered if the hair follicle openings in the balding area are not visible anymore. Also, dermatitis (including follicular erythema) associated with swelling, spots, and atrophic and hypertrophic scars are very often present. Histologically, increased inflammatory infiltrate is usually visible in the immediate vicinity of the follicles affected with scarring. The composition of an infiltrate indicates a given type of cicatricial alopecia. In fact, the current classification of primary cicatricial alopecia is mainly based on the predominating cells of the inflammatory infiltrate.^1,10–12

These disorders are divided into: lymphocytic, neutrophilic, mixed, or non-specific.

The results of immunofluorescence can be another diagnostic indicator, especially in the case of lupus erythematosus or bullous dermatoses in which damaged follicles will be eventually destroyed and replaced with scar-like fibrous tissue.^12,13

Dermatoscopy and direct immunofluorescence are also taken into consideration as alopecia diagnostic tools. Microarray analysis also enables to distinguish the subtypes of alopecia. Unfortunately, our understanding of the etiology and pathogenesis of cicatricial alopecia is still very incipient. The progress has been hindered by a poor understanding of the course of the disease, its incoherent and not precise description in the literature, absence of final molecular markers for any of the recognized form of the cicatricial alopecia, and finally because of an unpredictable and incomplete response to the treatment.^10,14,15

Therapeutic perspectives

Pseudopelade treatment is frustrating and usually does not bring satisfactory results. The main point of scarring alopecia therapy is stopping the progression of changes and possibly removal of their causes.^1,3

Therapy attempts to use antimalarial drugs, isoniazid, dapsone, and non-steroidal anti-inflammatory drugs. Relatively best results are obtained by oral steroids (e.g. Prednisone 40–80 mg for 2 weeks, followed by dose-reducing). These drugs are also recommended in topical therapy, especially for steroids having high potency in occlusion. Another way is intradermal administration of corticosteroids into the lesions.^1,32

Other methods are mainly experimental. Shapiro et al.⁵³ reported promising results use of pioglitazone hydrochloride in a dose of 15 mg per day (PPAR-γ agonist) among patients with lichen planus on the scalp. A total of 50% of patients responded to treatment as determined by the reduction of inflammatory cells and the clinically based on the reduction of itching and skin inflammation. However, increased incidence of bladder cancer in rodents after systemic administration of pioglitazone led to topical recommendation as an alternative.

Surgical intervention is generally the best method of treatment for scarring alopecia. Such therapy may consist in:

Removal of scarring tissue and surrounding the loss by healthy skin;

Lobe transplant the scalp;

Hair transplant.^1,54

We undertake surgical treatment mostly in young patients where scar is stable and does not exceed 30% of the surface of the scalp. Unfortunately these method are characterized by certain restrictions. First, in many cases you cannot be sure that there will be no recurrence and that the new process will affect the place after treatment.⁵⁵

Promising results have been reported by adding 5% minoxidil to hair transplant therapy. However, neither group paid attention to the lasting effects of this type of therapy.⁵⁶ Wang’s group⁵⁷ evaluated the technique of synchronous transplantation of hair follicles in the treatment of scarring alopecia as consequences of burns. Transplanted hair grew well in a natural way in 96.5% of cases. The authors found that the perforation technique and synchronous transplantation of hair follicles was safe and effective. The hair transplanted into the cicatricial lesions grew well and showed a high survival rate.

Often, a sufficient form of action is covering unsightly scars by wearing a wig. This option is available and requires no large financial outlay. Also important to obtain good therapeutic results and enhance the wellbeing of the patient is support from the family and the patient’s environment as well as psychotherapy.^32,58,59

Conclusion

Footnotes

Declaration of conflicting interests

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding

This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

References

Burgdorf

WHC

Plewig

Wolff

. (eds) (2010) Braun-Falco’s Dermatology. Lublin: Choroby Włosów (Wolff H).

Rongioletti

Christana

(2012) Cicatricial (scarring) alopecias: An overview of pathogenesis, classification,diagnosis, and treatment. American Journal of Clinical Dermatology 13(4): 247–260.

Harries

Trueb

Tosti

. (2009) How not to get scar(r)ed: Pointers to the correct diagnosis in patients with suspected primary cicatricial alopecia. British Journal of Dermatology 160: 482–501.

Whiting

(2001) Cicatricial alopecia: Clinico-pathological findings and treatment. Clinical Dermatology 19: 211–225.

Karnik

Smetanick

McKormick

. (2005) Microarray-based gene expression profiling in primary cicatricial alopecia implicates p53-dependent abnormal cytokine production, concurrent apoptosis and tissue remodelling in disease pathogenesis. Journal of Investigative Dermatology 124: A79.

Stenn

Cotsarelis

Price

(2006) Report from the cicatricial alopecia colloquium. Journal of Investigative Dermatology 126: 539–541.

Tiede

Kloepper

Bodo

. (2007) Hair follicle stem cells: Walking the maze. European Journal of Cell Biology 86: 355–376.

Botchkarev

Botchkareva

Peters

. (2004) Epithelial growth control by neurotrophins: Leads and lessons from the hair follicle. Progress in Brain Research 146: 493–513.

Stenn

Paus

(2001) Controls of hair follicle cycling. Physiological Reviews 81: 449–494.

10.

Rashid

Thomas

(2010) Androgenic pattern presentation of scarring and inflammatory alopecia. Journal of the European Academy of Dermatology and Venereology 24: 979–980.

11.

Meyer

Klatte

Dinh

. (2008) Evidence that the bulge region is a site of relative immune privilege in human hair follicles. British Journal of Dermatology 159: 1077–1085.

12.

Cotsarelis

(2006) Epithelial stem cells: A folliculocentric view. Journal of Investigative Dermatology 126: 1459–1468.

13.

Harries

Meyer

Paus

(2009) Hair loss as a result of cutaneous autoimmunity: Frontiers in the immunopathogenesis of primary cicatricial alopecia. Autoimmunity Reviews 8: 478–483.

14.

Schneider

Schmidt-Ullrich

Paus

(2009) The hair follicle as a dynamic miniorgan. Current Biology 19: R132–142.

15.

Paus

Nickoloff

Ito

(2005) A ‘hairy’ privilege. Trends in Immunology 26: 32–40.

16.

Kloepper

Tiede

Brinckmann

. (2008) Immunophenotyping of the human bulge region: the quest to define useful in situ markers for human epithelial hair follicle stem cells and their niche. Experimental Dermatology 17: 592–609.

17.

Ito

Liu

Yang

. (2005) Stem cells in the hair follicle bulge contribute to wound repair but not to homeostasis of the epidermis. Nature Medicine 11: 1351–1354.

18.

Christoph

Muller-Rover

Audring

. (2000) The human hair follicle immune system: Cellular composition and immune privilege. British Journal of Dermatology 142: 862–873.

19.

Reithmayer

Meyer

Kleditzsch

. (2009) Human hair follicle epithelium has an antimicrobial defence system that includes the inducible antimicrobial peptide psoriasin (S100A7) and RNase 7. British Journal of Dermatology 161: 78–89.

20.

Waldmann

(2006) Immunology: Protection and privilege. Nature 442: 987–988.

21.

Ito

Bettermann

. (2004) Collapse and restoration of MHC class-I-dependent immune privilege: Exploiting the human hair follicle as a model. American Journal of Pathology 164: 623–634.

22.

Ito

Saatoff

. (2008) Maintenance of hair follicle immune privilege is linked to prevention of NK cell attack. Journal of Investigative Dermatology 128: 1196–1206.

23.

Ito

Kromminga

. (2005) Human hair follicles display a functional equivalent of the hypothalamic-pituitary-adrenal axis and synthesize cortisol. FASEB Journal 19: 1332–1334.

24.

Gilhar

Paus

Kalish

(2007) Lymphocytes, neuropeptides, and genes involved in alopecia areata. Journal of Clinical Investigation 117: 2019–2027.

25.

Ohyama

Terunuma

Tock

. (2006) Characterization and isolation of stem cell-enriched human hair follicle bulge cells. Journal of Clinical Investigation 116: 249–260.

26.

Rosenblum

Yancey

Olasz

. (2006) CD200, a “no danger” signal for hair follicles. Journal of Dermatological Science 41: 165–174.

27.

Pozdnyakova

Mahalingam

(2008) Involvement of the bulge region in primary scarring alopecia. Journal of Cutaneous Pathology 35: 922–925.

28.

Wenzel

Henze

Brahler

. (2005) The expression of human leukocyte antigen-DR and CD25 on circulating T cells in cutaneous lupus erythematosus and correlation with disease activity. Experimental Dermatology 14: 454–459.

29.

Wenzel

Uerlich

Worrenkamper

. (2005) Scarring skin lesions of discoid lupus erythematosus are characterized by high numbers of skin-homing cytotoxic lymphocytes associated with strong expression of the type I interferon-induced protein MxA. British Journal of Dermatology 153: 1011–1015.

30.

Wenzel

Zahn

Bieber

. (2009) Type I interferon-associated cytotoxic inflammation in cutaneous lupus erythematosus. Archives of Dermatological Research 301: 83–86.

31.

Wenzel

Zahn

Mikus

. (2007) The expression pattern of interferon-inducible proteins reflects the characteristic histological distribution of infiltrating immune cells in different cutaneous lupus erythematosus subsets. British Journal of Dermatology 157: 752–757.

32.

Karnik

Stenn

(2012) Cicatricial Alopecia Symposium 2011: Lipids, Inflammation and Stem Cells. Journal of Investigative Dermatology 132: 1529–1531.

33.

Panicker

Ganguly

Consolo

. (2012) Sterol intermediates of cholesterol biosynthesis inhibit hair growth and trigger an innate immune response in cicatricial alopecia. PLoS One 7(6): e38449.

34.

Al-Zaid

Vanderweil

Zembowicz

. (2011) Sebaceous gland loss and inflammation in scarring alopecia: A potential role in pathogenesis. Journal of the American Academy of Dermatology 65(3): 597–603.

35.

Mirmirani

Karnik

(2009) Lichen planopilaris treated with a peroxisome proliferator-activated receptor gamma agonist. Archives of Dermatology 145: 1363–1366.

36.

Karnik

Tekeste

McCormick

. (2009) Hair follicle stem cell-specific PPARgamma deletion causes scarring alopecia. Journal of Investigative Dermatology 129: 1243–1257.

37.

Zamolo

Coklo

Santini Dusevic

. (2005) Expression of p53 and apoptosis in discoid lupus erythematosus. Croatian Medical Journal 46: 678–684.

38.

Wood

Flenniken

Osborne

. (2005) Two mouse mutations mapped to chromosome 11 with differing morphologies but similar progressive inflammatory alopecia. Experimental Dermatology 14: 373–379.

39.

Hiroi

Ito

Seo

. (2006) Male New Zealand Black/KN mice: A novel model for autoimmune-induced permanent alopecia? British Journal of Dermatology 155: 437–445.

40.

Peters

Arck

Paus

(2006) Hair growth inhibition by psychoemotional stress: A mouse model for neural mechanisms in hair growth control. Experimental Dermatology 15: 1–13.

41.

Peters

Botchkarev

Botchkareva

. (2001) Hair-cycle-associated remodeling of the peptidergic innervation of murine skin, and hair growth modulation by neuropeptides. Journal of Investigative Dermatology 116: 236–245.

42.

Arck

Handjiski

Hagen

. (2001) Indications for a ‘brain-hair follicle axis (BHA)’: Inhibition of keratinocyte proliferation and up-regulation of keratinocyte apoptosis in telogen hair follicles by stress and substance P. FASEB Journal 15: 2536–2538.

43.

Peters

Liotiri

Bodo

. (2007) Probing the effects of stress mediators on the human hair follicle: Substance P holds central position. American Journal of Pathology 171: 1872–1886.

44.

Hepper

Anadkat

(2011) Scarring alopecia associated with the epidermal growth factor receptor inhibitor erlotinib. Journal of the American Academy of Dermatology 64(5): 996–998.

45.

Brooke

Griffiths

(2001) Folliculitis decalvans. Clinical and Experimental Dermatology 26: 120–122.

46.

Horenstein

Simon

(2007) Investigation of the hair follicle inner root sheath in scarring and non-scarring alopecia. Journal of Cutaneous Pathology 34: 762–768.

47.

Azurdia

Graham

Weismann

. (2000) Acne keloidalis in caucasian patients on cyclosporin following organ transplantation. British Journal of Dermatology 143: 465–467.

48.

Bardazzi

Landi

Orlandi

. (1999) Graham Little-Piccardi-Lasseur syndrome following HBV vaccination. Acta Dermato-Venereologica 79: 93.

49.

Patton

Lynch

Fung

. (2007) Chronic atrophic erosive dermatosis of the scalp and extremities: A recharacterization of erosive pustular dermatosis. Journal of the American Academy of Dermatology 57: 421–427.

50.

Meier

Mutasim

(2010) Scarring alopecia followed by a progressive eruption. Journal of the American Academy of Dermatology 63(2): e19–20.

51.

Viglizzo

Verrini

Rongioletti

(2004) Familial Lassueur-Graham-Little-Piccardi syndrome. Dermatology 208: 142–144.

52.

Singh

Saikia

. (2012) Pseudopelade of Brocq in two brothers: Possible role of hereditary factors in the pathogenesis. Indian Journal of Dermatology Venereology and Leprology 78(5): 637–640.

53.

Shapiro

(2008) Cicatricial alopecias. Dermatologic Therapy 21(4): 211.

54.

House

Welsh

English

3rd (2012) Sarcoidosis-induced alopecia. Dermatology Online Journal 18(8): 4.

55.

Meyer-Gonzalez

Bisanga

(2012) Body-hair transplant for cicatricial alopecia. Actas Dermo-sifiliograficas 103(2): 163–164.

56.

Tyagi

Singh

(2010) A new approach to treating scarring alopecia by hair transplantation and topical minoxidil. Indian Journal of Dermatology Venereology and Leprology 76(2): 215.

57.

Wang

Fan

Chai

(2009) The treatment of cicatricial alopecia after burn with the technique of synchronously perforating and transplanting hair follicular-units. Zhonghua Shao Shang Za Zhi 25(6): 411–414.

58.

Donovan

Shapiro

. (2012) A review of scalp camouflaging agents and prostheses for individuals with hair loss. Dermatology Online Journal 18(8): 1.

59.

Banka

Bunagan

Dubrule

. (2012) Wigs and hairpieces: Evaluating dermatologic issues. Dermatologic Therapy 25(3):260–266.

Cicatricial alopecia: What’s new in etiology?

Abstract

Keywords

Clinical features of cicatricial alopecia

Classification of cicatricial alopecia

Etiology of cicatricial alopecia

Diagnosis of cicatricial alopecia

Therapeutic perspectives

Conclusion

Footnotes

Declaration of conflicting interests

Funding

References